Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30998305 | 0.80 | ALDH1A1 (0.62) | PTPN1KDM4EALDH1A1GSK3B | |
| SCHEMBL1438181 | 0.80 | ALDH1A1 (0.62) | PTPN1KDM4EALDH1A1GSK3B | |
| SCHEMBL17666650 | 0.80 | HSP90AB1 (0.44) | GRIN2BGRIN1KDM4EALDH1A1 | |
| SCHEMBL6171965 | 0.78 | GSK3B (0.52) | ALDH1A1GSK3B | |
| SCHEMBL2071336 | 0.78 | GSK3B (0.52) | PTPN1KDM4EALDH1A1GSK3B | |
| Bromide SCHEMBL4892809 | 0.78 | ALDH1A1 (0.60) | PTPN1KDM4EALDH1A1GSK3B | |
| SCHEMBL1849723 | 0.78 | PTPN1 (0.52) | PTPN1GRIN2BGRIN1KDM4EALDH1A1 | |
| SCHEMBL30518645 | 0.78 | GSK3B (0.52) | PTPN1KDM4EALDH1A1GSK3B | |
| SCHEMBL29555996 | 0.78 | GSK3B (0.52) | ALDH1A1GSK3B | |
| Bromide SCHEMBL3578187 | 0.77 | PTPN1 (0.50) | PTPN1GRIN2BGRIN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649143-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | Novartis AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-12145909-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B | NOVARTIS AG (CH) | 2024-11-19 | — | — | US | disclosed |
| WO-2024150146-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | NOVARTIS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| EP-4282412-A2 | N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Novartis AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-3974420-B1 | N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | NOVARTIS AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| EP-3974420-B1 | N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | NOVARTIS AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220274925-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | US | disclosed |
| US-9540324-B2 | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B | LUC THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540324-B2 | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B | LUC THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-3036221-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | Luc Therapeutics, Inc. (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2016049165-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049165-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| WO-2015048507-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015048507-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274925-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | PTPN1 237/4885GRIN2B 4/4885GRIN1 5/4885 |
| US-12145909-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | PTPN1 237/4885GRIN2B 4/4885GRIN1 5/4885 |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | PTPN1 1292/4885GRIN2B 4/4885GRIN1 6/4885 |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | PTPN1 1292/4885GRIN2B 4/4885GRIN1 6/4885 |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | PTPN1 1292/4885GRIN2B 4/4885GRIN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.